| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/24/2004 | WO2004018044A8 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2003099221A3 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 06/24/2004 | WO2003090690A3 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such |
| 06/24/2004 | WO2003086311A3 Methods for treating tweak-related conditions |
| 06/24/2004 | WO2003075856A3 Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
| 06/24/2004 | WO2003057200A3 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 06/24/2004 | WO2003053966A8 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 06/24/2004 | WO2003051841A3 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 06/24/2004 | WO2003049686A3 Stabilization of hypoxia inducible factor (hif) alpha |
| 06/24/2004 | WO2003014309A3 Interleukin-1 receptors in the treatment of diseases |
| 06/24/2004 | WO2002092758A9 Gastrokines and derived peptides including inhibitors |
| 06/24/2004 | WO2002092594A8 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 06/24/2004 | WO2002036072A3 Method for short-term and long-term drug dosimetry |
| 06/24/2004 | US20040122235 such as N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; for treating diseases in which increasing glucokinase activity is beneficial (diabetes) |
| 06/24/2004 | US20040122125 Lactone compounds as novel photoinitiators |
| 06/24/2004 | US20040122100 which contain EP1 agonist (which activate EP1 receptor that is subtype of prostaglandin E2 receptor) as an active ingredient |
| 06/24/2004 | US20040122084 7-Methyl-3.6,10,15-tetraoxapentacyclo [12.2.1.02,4. 05,7. 09,13]heptadec-1(17)-ene-11,16-dione derivatives; antitumor, -proliferative, -carcinogenic agents; viricides;DNA polymerase inhibitors; bactericides; solubility; stability; injections |
| 06/24/2004 | US20040122082 A drug, a food, a beverage or a feed, each having an effective ingredient of a coumarin and/or a chroman compound having an enhancing action for nerve growth factors (NGF) production; nervous system disorders; Alzheimer's disease; plant extracts |
| 06/24/2004 | US20040122076 The use of 1-(iso)indolylsulfonamido-),4-(alkylamido-)benzenes and derivatives as 5-Ht6receptor antagonists; Alzheimer's disease; neurodegenerative diseases; prophylaxis |
| 06/24/2004 | US20040122070 Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis; Alzheimer's disease |
| 06/24/2004 | US20040122056 dissolving crude omeprazole in a solvent or a mixture of solvents in which omeprazole is freely soluble, and precipitating crystal form of omeprazole with a solvent in which omeprazole is poorly soluble. |
| 06/24/2004 | US20040122052 Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group or derivative; selectively inhibit TNF alpha, useful in treating inflammation and effecting relaxation of airway smooth muscle |
| 06/24/2004 | US20040122047 Substituted tetrahydroisoquinolines |
| 06/24/2004 | US20040122046 NPY-5 antagonists |
| 06/24/2004 | US20040122044 Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations |
| 06/24/2004 | US20040122039 Pyrazolo[1,5-a]pyridines and medicines containing the same |
| 06/24/2004 | US20040122036 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
| 06/24/2004 | US20040122032 for treating neurodegenerative disorders; mixture with other active ingredients; 1-{2-(3'-chlorobiphenyl-4-yl)-2-oxoethyl}-4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyridine for example; Alzheimer's disease, cerebral edema |
| 06/24/2004 | US20040122030 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide |
| 06/24/2004 | US20040122027 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 06/24/2004 | US20040122023 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine |
| 06/24/2004 | US20040122021 High optical purity of both levoratatory and dextrorotatory forms; simple, economic synthesis |
| 06/24/2004 | US20040122020 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 06/24/2004 | US20040122018 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives; use in combination with antineoplastic agents such as cisplatin |
| 06/24/2004 | US20040122010 Treatment of neuropathy |
| 06/24/2004 | US20040122006 such as 7-[(2-aminophenyl)sulfanyl]-2H-1,4-benzoxazin-3(4H)-one; oxidation/reduction; deblocking/deprotectiing; cardiovascular disorders |
| 06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
| 06/24/2004 | US20040122002 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof |
| 06/24/2004 | US20040121998 CRF antagonistic quino- and quinazolines |
| 06/24/2004 | US20040121997 20-hydroxyeicosatetraenoic acid production inhibitors |
| 06/24/2004 | US20040121993 for the reduction of cholesterol in blood, and treatment of fatty liver, hyperglycemia and diabetes |
| 06/24/2004 | US20040121976 Anti-inflammatory vectors |
| 06/24/2004 | US20040121972 Methylenetetrahydrofolate reductase inhibitors and uses thereof |
| 06/24/2004 | US20040121962 Prodrugs of excitatory amino acids |
| 06/24/2004 | US20040121940 Anticancer prodrugs, enhance enzymatic activation rates |
| 06/24/2004 | US20040121387 Comprises nucleotide sequences coding caspase 8 inhibitory protein for use in the treatment of alzheimer's, parkinson's, arthritic, septic, cardiovascular, inflammatory, osteoporotic and ischemic reperfusion injuries/disorders |
| 06/24/2004 | US20040121376 Antisense modulation of interleukin-5 signal transduction |
| 06/24/2004 | US20040121327 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests |
| 06/24/2004 | US20040121316 Method and compositions for identifying anti-HIV therapeutic compounds |
| 06/24/2004 | US20040121030 Extract from the pods of lupin seeds containing lupeol |
| 06/24/2004 | US20040121028 Plant based agents as bioavailability / bioefficacy enhancers for drugs and nutraceuticals |
| 06/24/2004 | US20040121008 Process for producing sustained release preparation |
| 06/24/2004 | US20040120999 Liposome containing remedy for vascular disease |
| 06/24/2004 | US20040120970 vaccine is for administration in the submucosa of the labiae is an attenuated form of a horse pathogenic bacterium |
| 06/24/2004 | US20040120954 expression of PEX without a catalytic site of MT1-MMP on a cell surface directly prevents an association of two enzymes and inhibits the activation of proMMP-2 in a dose-dependent manner |
| 06/24/2004 | US20040120952 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 06/24/2004 | US20040120936 Enhanced composition for treatment of obesity |
| 06/24/2004 | US20040120935 Genetically modified yt cell line and use thereof |
| 06/24/2004 | CA2509238A1 Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 06/24/2004 | CA2509170A1 Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 06/24/2004 | CA2507987A1 A vegetable composition having blood enhancing properties |
| 06/23/2004 | EP1431347A1 Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these |
| 06/23/2004 | EP1431311A1 Immunotherapy of B-cell malignancies using anti-CD22 and anti-CD20 antibodies in combination |
| 06/23/2004 | EP1431294A1 Vascular wall-selective acat inhibitor |
| 06/23/2004 | EP1431293A1 Water-soluble phenylpyridazine derivatives and drugs containing the same |
| 06/23/2004 | EP1431292A1 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors |
| 06/23/2004 | EP1431291A1 1-Aryl-4-cyano-3-cyclopropylpyrazole derivatives as ectoparasiticidal agents |
| 06/23/2004 | EP1431290A1 Novel nitrogenous compound and use thereof |
| 06/23/2004 | EP1431286A2 Prodigiosin derivatives for treating cancer or viral diseases |
| 06/23/2004 | EP1431285A1 Reverse hydroxamic acid derivatives |
| 06/23/2004 | EP1431280A1 Aryl sulfamate derivatives |
| 06/23/2004 | EP1430934A1 Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 06/23/2004 | EP1430903A1 Use of proteasome inhibitors for the treatment of viral infections |
| 06/23/2004 | EP1430898A1 Receptor antagonist |
| 06/23/2004 | EP1430887A1 Powder for inhalation containing Tiotropium |
| 06/23/2004 | EP1430157A2 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430131A2 Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| 06/23/2004 | EP1430125A2 Sperm-specific cation channel, and uses therefor |
| 06/23/2004 | EP1430120A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| 06/23/2004 | EP1430111A1 Culture system for rapid expansion of human embryonic stem cells |
| 06/23/2004 | EP1430085A1 Leukocyte inactivation module |
| 06/23/2004 | EP1430060A2 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors. |
| 06/23/2004 | EP1430058A1 Sodium salt of an hiv integrase inhibitor |
| 06/23/2004 | EP1430057A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives |
| 06/23/2004 | EP1430051A1 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds |
| 06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 06/23/2004 | EP1430045A1 Pyrane derivatives as both ace- and nep-inhibitors |
| 06/23/2004 | EP1430043A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| 06/23/2004 | EP1430041A2 Novel sulfonic acid derivatives |
| 06/23/2004 | EP1430040A1 Benzothiazepine derivatives |
| 06/23/2004 | EP1430032A2 Substituted amides for the treatment of neurological disorders |
| 06/23/2004 | EP1430031A2 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 06/23/2004 | EP1430030A1 N-type calcium channel antagonists for the treatment of pain |
| 06/23/2004 | EP1430027A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 06/23/2004 | EP1430024A1 Alkyl urea retinoid agonists i |
| 06/23/2004 | EP1430023A1 Substituied urea retinoid agonists ii |